Germany plans to invest €300m in the private biotech company CureVac, giving Berlin a 23 per cent stake in the developer of a potential coronavirus vaccine that attracted interest from Donald Trump’s White House in March.
The company is due to start clinical trials for a Covid-19 vaccine this
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
